SAT0530 SPSAMRIS: A TIME AND RESOURCE SAVING ALTERNATIVE FOR DETECTION AND MONITORING OF DISEASE-RELATED JOINT CHANGES?. (June 2019)

• Record Type: Journal Article
• Authors: Sewerin, Philipp; Abrar, Daniel; Brinks, Ralph; Vordenbäumen, Stefan; Lautwein, Alexander; Schneider, Matthias; Ostendorf, Benedikt; Schleich, Christoph
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1357
• Page End: 1357
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.4841
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Standardized imaging scores in MRI are barley used in daily clinical practice whereby the high expenditure (in terms of time and staff) is often given as a reason. Objectives: To develop and evaluate a simplified version of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS). Methods: 19 patients with PsA according to CASPAR classification criteria with inadequate methotrexate response received anti-TNF treatment and were assessed by 3T MRI of the clinically dominant hand at baseline and after 6 months. Scoring was according to PsAMRIS. Items were reduced based on standard response mean (SRM) resulting in sPsAMRIS, which was compared to PsAMRIS by calculation of the total SRM and relative efficiency (RE) after bootstrapping. Results: PsAMRIS subscore of MCP3, 4, and PIP4 resulted in the highest SRM (-0.07 each) and were therefore included in sPsAMRIS. sPsAMRIS had higher SRM compared to PsAMRIS (-0.13 vs. -0.02) and a higher RE (29.46). PsAMRIS and sPsAMRIS highly correlated at baseline (r= 0.75; p < 0.01) and follow-up (r= 0.64; p= 0.01). Evaluation time was reduced from 471 to 142 seconds at baseline and from 478 to 133 seconds at follow-up (p < 0.001). Conclusion: The abbreviated MRI scoring system for PsA-related changes in hands, sPsAMRIS, showed a strong correlation with the well-evaluated PsAMRIS. Hence, sPsAMRIS can be considered as a time and resource saving alternative for semi-quantitative evaluation and monitoring of PsA related joint-pathology. Acknowledgement: The project was funded by a grant from the German "Bundesministerium für Bildung und Forschung"(BMBF), ArthroMark (01EC1009). Disclosure of Interests: Philipp Sewerin: None declared, Daniel Abrar: None declared, Ralph Brinks: None declared, Stefan Vordenbäumen: None declared, Alexander Lautwein: None declared, Matthias Schneider Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study., Speakers bureau: Chugai, Benedikt Ostendorf: None declared, Christoph Schleich: None declared